 | Up a level |
Cora, N. S., Sergio, B., Ugo, D. G., Giuseppe, P., Simon, C., Wassim, A., Angel, A. A. Jose, Gedske, D., Karim, F., Eliahu, G., Axel, H., Florence, J., Ray, M., Axel, S. M., Maria, P. Josep, Brieuc, S., Srikala, S., Tony, G., Charles, J. R. and Howard, I. S. (2017). The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Simon, C., Lefevre, C. Fortpied, Govaerts, A-S., Raveloarivahy, T., Bourhis, J., Evans, M., Klussmann, J. P., Leemans, C. R., Hunter, K. D., Singer, S., Nuyts, S., Willemse, E., Ansarin, M., Spriano, G., Golusinski, W., Giger, R., Boehm, A., Lopez, F. and Gregoire, V. (2022). Phase III study assessing the best of radiotherapy compared to the best of surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma. Ann. Oncol., 33 (7). S. S865 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041